Skip Navigation

Rheumatology 2008 47(1):45-49; doi:10.1093/rheumatology/kem313
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Antonelli, A.
Right arrow Articles by Ferrannini, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Antonelli, A.
Right arrow Articles by Ferrannini, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

CXCL10 ({alpha}) and CCL2 (β) chemokines in systemic sclerosis—a longitudinal study

A. Antonelli1, C. Ferri2, P. Fallahi1, S. M. Ferrari1, D. Giuggioli2, M. Colaci2, A. Manfredi2, S. Frascerra1, F. Franzoni1, F. Galetta1 and E. Ferrannini1

1Department of Internal Medicine, University of Pisa School of Medicine, Pisa and 2Department of Internal Medicine, Rheumatology Unit, University of Modena and Reggio Emilia School of Medicine, Modena, Italy.

Correspondence to: A. Antonelli, Department of Internal Medicine, University of Pisa School of Medicine, Via Roma, 67, I-56100, Pisa, Italy. E-mail: a.antonelli{at}med.unipi.it


  Abstract

Objectives. To measure serum levels of CXCL10 and CCL2 chemokines in patients with SSc, and relate the findings to clinical phenotype and disease progression.

Methods. Serum CXCL10 and CCL2 were assayed in 72 consecutive newly diagnosed SSc patients and in 72 sex- and age-matched controls. In 37 SSc and 37 controls, serum CXCL10 and CCL2 were re-evaluated 5 yrs later.

Results. SSc at onset showed significantly higher CXCL10 serum levels than controls (216 ± 126 vs 92 ± 53 pg/ml; P < 0.0001), as well as CCL2 (388 ± 172 vs 318 ± 120 pg/ml; P = 0.01). CXCL10 was significantly increased in SSc with interstitial lung involvement or with kidney involvement (P = 0.01 and P = 0.02, respectively). A significant decrease of CXCL10 was observed from the baseline after 5 yrs in SSc (137 ± 112 vs 270 ± 122 pg/ml, respectively; P < 0.0001), while no significant change was observed for CCL2 (418 ± 176 vs 405 ± 164 pg/ml; P = NS); the CCL2/CXCL10 ratio significantly increased at the fifth year (1.7 ± 0.8 vs 3.5 ± 2.5; P < 0.0001). No significant variations were observed in controls from the basal to the 5-yr evaluation with regards to CXCL10, CCL2 or CCL2/CXCL10 ratio.

Conclusions. Our study demonstrates high serum levels of CXCL10 (Th1) and CCL2 (Th2) chemokines in newly diagnosed SSc. High values of CXCL10 are associated with a more severe clinical phenotype (lung and kidney involvement). CXCL10 declined during the follow-up, while CCL2 remained unmodified, suggesting that the disease progresses from the early Th1 inflammatory condition to the advanced Th2-like stage.

KEY WORDS: CXCL10 (IP-10), CCL2 (MCP-1), Th1, Th2, Systemic sclerosis, Scleroderma

Submitted 7 May 2007; revised version accepted 29 October 2007.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.